ATP7B and Wilson disease: The standard of care for Wilson disease presents serious adverse effects and adherence issues1, thus c.1934T > G homozygous and compound heterozygous patients could benefit from a novel SBO therapeutic restoring ATP7B exon 6 inclusion.